Literature DB >> 29268397

Epidemiology, microbiology and treatment implications in adult patients hospitalized with pneumonia in different regions of China: a retrospective study.

Fan Liu1, Zehuai Wen2, Jia Wei3, Huiling Xue3, Yunqin Chen3, Weiguo Gao3, David Melnick4, Jesus Gonzalez5, Judith Hackett6, Xiaoyan Li2, Shizhou Deng1, Zhaolong Cao1.   

Abstract

BACKGROUND: Data describing epidemiology, clinical outcomes and treatment patterns, of hospitalised patients with pneumonia in China are limited. We aimed to describe such information among adult pneumonia patients in southern and northern China.
METHODS: We retrospectively reviewed electronic medical records of pneumonia patients aged ≥18 years, hospitalized between 2008 and 2013 at Guangdong Provincial Hospital of Chinese Medicine (n=3,636), southern China, and between 2010 and 2014 at Peking University People's Hospital, Beijing (n=1,689), northern China, in order to collect data on patient demographics, microbiology, clinical outcomes and treatment and resistance patterns.
RESULTS: The mean (SD) age of patients was 60.0 (21.4) and 64.4 (18.4) years in Guangdong and Beijing, respectively. Mean length of hospital stay was 12.1 and 20.8 days, and overall mortality was 2.9% and 8.0%, respectively. Gram-negative bacilli were most frequently isolated, predominantly Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa. Infection with these bacteria was associated with unfavourable clinical outcomes, and the antibiotic resistance among these bacteria increased between 2008-2010 and 2011-2013 in both regions of China. The treatment and choice of antibiotics slightly varied between the two regions based on the susceptible pathogens identified among their populations.
CONCLUSIONS: Of the pathogens identified, Staphylococcus aureus infection (particularly the methicillin-resistant S. aureus) was associated with poor clinical outcomes; however antibiotic resistance among S. aureus generally decreased during the study data collection periods. Also, disease severity was greater in Beijing as compared with Guangdong, and this may be associated with higher microbiological diagnosis rate and higher frequency of initial antibiotic modification among Beijing populations.

Entities:  

Keywords:  Antibacterial therapy; epidemiology; microbiology; pneumonia

Year:  2017        PMID: 29268397      PMCID: PMC5723798          DOI: 10.21037/jtd.2017.09.18

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  20 in total

Review 1.  Hospital-acquired pneumonia: risk factors, microbiology, and treatment.

Authors:  J P Lynch
Journal:  Chest       Date:  2001-02       Impact factor: 9.410

2.  Clinical and bacteriological profile of community acquired pneumonia in Shimla, Himachal Pradesh.

Authors:  S Bansal; S Kashyap; L S Pal; A Goel
Journal:  Indian J Chest Dis Allied Sci       Date:  2004 Jan-Mar

3.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

4.  Etiologies and treatment outcomes in patients hospitalized with community-acquired pneumonia (CAP) at Srinagarind Hospital, Khon Kaen, Thailand.

Authors:  Wipa Reechaipichitkul; Viraphong Lulitanond; Puntip Tantiwong; Ratchanee Saelee; Veeradej Pisprasert
Journal:  Southeast Asian J Trop Med Public Health       Date:  2005-01       Impact factor: 0.267

5.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

6.  Investigation of a multiyear multiple critical care unit outbreak due to relatively drug-sensitive Acinetobacter baumannii: risk factors and attributable mortality.

Authors:  R Kaul; J A Burt; L Cork; H Dedier; M Garcia; C Kennedy; J Brunton; M Krajden; J Conly
Journal:  J Infect Dis       Date:  1996-12       Impact factor: 5.226

Review 7.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 8.  The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review.

Authors:  Leon Peto; Behzad Nadjm; Peter Horby; Ta Thi Dieu Ngan; Rogier van Doorn; Nguyen Van Kinh; Heiman F L Wertheim
Journal:  Trans R Soc Trop Med Hyg       Date:  2014-04-29       Impact factor: 2.184

Review 9.  Community-acquired pneumonia: an Asia Pacific perspective.

Authors:  Chong-Kin Liam; Yong-Kek Pang; Shyamala Poosparajah; Keong-Tiong Chua
Journal:  Respirology       Date:  2007-03       Impact factor: 6.424

10.  Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH.

Authors:  Francesco Blasi; Javier Garau; Jesús Medina; Marco Ávila; Kyle McBride; Helmut Ostermann
Journal:  Respir Res       Date:  2013-04-15
View more
  2 in total

1.  Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.

Authors:  Xiaoju Lv; Jeff Alder; Li Li; William O'Riordan; Michael J Rybak; Hui Ye; Ruiping Zhang; Zhongqi Zhang; Xu Zhu; Mark H Wilcox
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

2.  The effect of oral care intervention on pneumonia hospitalization, Staphylococcus aureus distribution, and salivary bacterial concentration in Taiwan nursing home residents: a pilot study.

Authors:  Tien-Cheng Chiang; Ming-Shyan Huang; Po-Liang Lu; Shun-Te Huang; Ying-Chu Lin
Journal:  BMC Infect Dis       Date:  2020-05-27       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.